What does a Paragraph IV certification cover?
It is a formal notice tied to an Abbreviated New Drug Application. The generic (or other ANDA applicant) certifies against Orange Book patents and must notify the NDA holder and patent owners with a detailed statement of the factual and legal basis for its position.
Why do brands often sue quickly after the notice?
For a qualifying patent, an infringement suit filed within 45 days after receipt of Paragraph IV notice can trigger a 30-month stay of FDA approval under 21 U.S.C. 355(j)(5)(B)(iii). The 30 months are measured from receipt of the notice, subject to the statute's exceptions and provisions allowing the period to end earlier or be adjusted. FDA and patent counsel should verify which patents qualify and the controlling receipt dates.
How is this different from an ordinary infringement notice letter?
Paragraph IV notice is embedded in the FDA/Orange Book framework. Ordinary commercial notice letters outside Hatch-Waxman do not start the same 30-month stay machine. Damages, venue, and PTAB choices also sit next to regulatory timing in a way consumer-electronics cases usually do not.
What should an ANDA applicant do after sending or receiving related papers?
Calendar receipt of the Paragraph IV notice, the 45-day filing window, and the separate FDA and litigation deadlines. The complaint may trigger the stay if the statutory conditions are met, but it does not start a fresh 30-month period. Align the detailed statement with the litigation positions you are prepared to defend. See the ANDA 30-month stay and Orange Book brand FAQs.
Where should brand-side readers go?
See the Orange Book brand FAQ and the choose-district-or-ITC pages for plaintiff framing. This page is written mainly for recipients and applicants navigating the notice.